Cancer patients who undergo surgery are often left with a frightening question: Did the surgeons get all the cancerous cells? No one wants a recurrence of disease, but additional treatments such as radiation or chemotherapy have significant side effects. That’s why Viktor Adalsteinsson PhD ’15 has been developing tools to support better-informed treatment decisions: so-called “liquid biopsies” that can detect the presence of cancer from a simple blood test.
KI announced a major strategic partnership with Ortho-McNeil-Janssen Pharmaceuticals, Inc., and its affiliates, called TRANSCEND, whereby the parties will begin to collaborate in multiple areas of oncology research and technology development.
MIT has announced a $100 million gift from Koch Industries executive and MIT alumnus David H. Koch that will usher in new paradigms in highly integrative cancer research. The gift will bring together MIT scientists and engineers under one roof to develop new and powerful ways to detect, diagnose, treat, and manage this often deadly disease.